CARROTNSTICKS MARKETING

US drugmakers turn to China for licensing deals

Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global ​rights to an experimental cancer drug, making ‌it the latest US drugmaker to license …

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by